This might have been due to the multikinase inhibitors inhibiting not only VEGFR-1, -2, and -3, but also other signal pathways associated with proliferation, invasion and metastasis of the tumor such as platelet-derived growth factor receptor (PDGFR), stem-cell factor receptor (KIT), FMS-like tyrosine kinase 3 (FLT3), and colony-stimulating factor 1 receptor (CSF-1R), while bevacizumab inhibits only VEGF32-34. The gene discussed is KIT; the disease is neoplasm.